Previous studies demonstrated the efficacy and safety of prolonged-release melatonin in children and adolescents with neurodevelopmental and behavioral disorders. The long-term effectiveness and safety of prolonged-release melatonin treatment were assessed in 88 children (42 girls and 46 boys) with neurodevelopmental disorders. These patients participated in a compassionate-use program with the drug Circadin (2 mg; Neurim Pharmaceuticals, Tel Aviv, Israel) in France, and received treatment in the context of regular care by a specialized physician. The study involved a structured questionnaire for the parents, comprising a combination of multiple-choice and numeric questions addressing sleep onset/offset, sleep quality problems, and mood. The dose of melatonin ranged from 4-6 mg, and treatment duration ranged from 6-72 months. Within 3 months, sleep latency with prolonged-release melatonin decreased by 44.0% (P < 0.001), sleep duration increased by 10.1% (P < 0.001), the number of awakenings decreased by 75% (P < 0.001), and sleep quality improved by 75%, compared with baseline (P < 0.001). No serious adverse events or treatment-related comorbidities were reported. Prolonged-release melatonin remains a safe, effective therapy for the long-term treatment of sleep disorders in children with neurodevelopmental disorders.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.pediatrneurol.2011.02.001 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Patient-level analysis of the cost and variation in melatonin prescribing patterns in those under 18 in the North East of England.
BMJ Paediatr Open
December 2024
Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle Upon Tyne, UK
Background: Melatonin is widely used to promote sleep in both normally developing children and adolescents and those with neurodevelopmental disorders. It has an evidence base as both hypnotic and chronobiotic although the optimum dose and timing remain unclear. There are now a wide variety of different preparations of melatonin both immediate and prolonged release.
View Article and Find Full Text PDFEffects of Approved Pharmacological Interventions for Insomnia on Mood Disorders: A Systematic Review.
Clin Neuropsychiatry
October 2024
Department of Surgical, Medical and Molecular Pathology, Critical and Care Medicine, University of Pisa, Pisa, Italy, Department of Neuroscience, Azienda Ospedaliera Universitaria Pisana (AUOP), Pisa, Italy.
Objective: Insomnia can be a contributing factor, a comorbid disorder, or a transdiagnostic element to several mental disorders, including mood disorders (MDs). A recent meta-analysis has already shown the effectiveness of cognitive behavioral treatment (CBT) for insomnia that is comorbid with MDs. This work aimed to systematically review data on pharmacological insomnia treatment in the context of MDS.
View Article and Find Full Text PDFTemazepam or Melatonin Versus Placebo for the Treatment of Insomnia in Advanced Cancer: A Three-Arm, Double-Blind, Phase III, Multicenter, Randomized Clinical Trial.
J Palliat Med
October 2024
Palliative Medicine, Centre for Cancer Research, Faculty of Medicine, Dentistry and Health Sciences, St Vincent's Hospital and The University of Melbourne, Melbourne, Australia.
Article Synopsis
- Sleep disturbances are common in advanced cancer patients, affecting 30-78% of them, yet there are few rigorous studies on treatment options.
- This study tested the effectiveness and safety of temazepam and prolonged-release melatonin against a placebo for treating insomnia in advanced cancer patients, with a total of 21 participants.
- Both temazepam and melatonin resulted in a significant reduction in insomnia severity compared to placebo, but did not improve overall quality of life; further research with more participants is needed to confirm these results.
Melatonin Bioavailability After Oral Administration of a New Delayed-Release Form in Healthy Male Volunteers.
Drugs R D
September 2024
, 127 chemin de Bois Vieux, 26400, Aouste-sur-Sye, France.
Background: Two main types of galenic formulation, immediate release and prolonged release, have been developed to optimize melatonin bioavailability. We recently described the kinetic profile of a prolonged-release form generating a peak of plasma melatonin 1 h (T) after intake, followed by a prolonged decay over time. We have developed a new oral form of melatonin with the aim of producing a melatonin peak several hours after intake.
View Article and Find Full Text PDFEffect of graduated drug therapy for moderate-to-severe chronic insomnia on the severity of disease: an observational study in Germany.
J Clin Sleep Med
January 2025
Interdisziplinäres Schlafmedizinisches Zentrum, Charité - Universitätsmedizin Berlin, Berlin, Germany.
Study Objectives: Severe chronic insomnia is a common sleep disorder that is mostly persistent and needs to be treated. Pharmacologic treatment options and guidelines are sparse, particularly for long-term treatment. Our study aimed to investigate a graduated therapy scheme for moderate-to-severe chronic insomnia in practice, considering the effects on self-reported sleep quality and quality of life.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!